Clinical trial · Observational
Triadic Expectations: Decision Making in the Context of Cancer Treatment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this pilot study is to test the feasibility of identifying and interviewing healthcare triads (patients, loved ones and oncologists) in a research study and evaluate the influences of patients' loved ones and oncologists on cancer treatment decision-making. the study team plans to explore concordance or discordance within the triad about the decisions, and also assess decisional conflict, regret and distress. Study methods involve interviewing a total of 75 patients, their loved ones and oncologists about past cancer treatment decisions. Analysis will consist mainly of qualitative content analysis. The investigators do not anticipate risk or safety issues beyond loss of confidentiality or minimal discomfort while discussing a cancer treatment decision.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Health Care Decision Making | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Health Care Triads
- description
- This is an exploratory pilot study of 25 health care triads. Triads will include: (1) a patient diagnosed with advanced cancer, (2) a loved one, and (3) an oncology provider.
Primary outcomes (2)
- measure
- Decisional Regret
- timeFrame
- three to four months after treatment decision
- description
- This outcome will be measured with an interviewer-administered survey.
- measure
- Decisional concordance or discordance among members of triads
- timeFrame
- three to four months after treatment decision
- description
- This outcome will be measured with an interviewer-administered survey.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Oncologist Inclusion Criteria: * At least 18 years of age; * An attending physician or fellow at Duke University Medical Center; * Medical, surgical or radiation oncologist; * Provides care to patients diagnosed with at least one of the following conditions: * Recurrent or refractory Acute Myeloid Leukemia (AML), also known as acute myelogenous leukemia or acute nonlymphocytic leukemia (ANLL); * Chronic myeloid leukemia (CML) in blast phase; * Non-hodgkin lymphoma (NHL), relapsed or refractory; * Acute lymphocytic leukemia (ALL), relapsed or refractory; * Metastatic pancreatic cancer; * Metastatic colorectal cancer; * Metastatic gastro-esophageal cancer; * Metastatic Cholangiocarcinoma. Patient Inclusion Criteria: * At least 18 years of age; * A Duke patient receiving care from an oncology provider who is enrolled in the study; * Currently admitted to the Duke University hematological malignancies in-patient service OR being seen at Duke's outpatient GI cancer clinic; * Made a cancer treatment decision in the last 3 months; * Diagnosed with one of the following: * Recurrent or refractory Acute Myeloid Leukemia (AML), also known as acute myelogenous leukemia or acute nonlymphocytic leukemia (ANLL); * Chronic myeloid leukemia (CML) in blast phase; * Non-hodgkin lymphoma (NHL), relapsed or refractory; * Acute lymphocytic leukemia (ALL), relapsed or refractory; * Metastatic pancreatic cancer; * Metastatic colorectal cancer; * Metastatic gastro-esophageal cancer; * Metastatic Cholangiocarcinoma. Loved One (friend/family) Inclusion Criteria: * At least 18 years of age; * Identified by patient as influential in a recent (within 3 months) treatment decision; * Able and willing to complete the study interview in person or by telephone. Exclusion for all Subjects: * Lacking capacity to give legally effective consent; * Does not read or understand English.
References
Publications (0)
Data not yet available